Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 66

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 66
---
 -   Balance, June 30, 2025 (Successor)   74,151   $22.67    9.82   Options exercisable as of June 30, 2025   8,413   $77.16    9.61  

The Company estimated the fair value of the stock options during the
six months ended June 30, 2025 and for the period from February 14, 2024 to June 30, 2024 using Black-Scholes with the following assumptions.

    Six Months Ended  June 30,  
    February 14, 2024 to June 30, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Risk-free interest rate 
     3.98% to 4.01%  
     4.46% to 4.79% 
  
    Expected life (in years) 
     5.0  
     5.0 to 6.0 
  
    Expected dividend yield 
     -%  
     -% 
  
    Expected volatility 
     104.54% to 121.09%  
     143.4% to 153.5% 

There were no stock options granted during the predecessor period from
January 1, 2024 and February 13, 2024.

For
the period from February 14, 2024 through June 30, 2024, the Company recorded stock-based compensation expense of $1,485,027, of which
$849,952 was related to R&D and $635,075 was related to general and administrative. For the period from January 1, 2024 through February
13, 2024, Predecessor recorded an immaterial amount of stock-based compensation expense.

For
the three months ended June 30, 2025, the Company recorded stock-based compensation expense of $183,328, of which $53,821 was related
to research and development and $129,507 was related to general and administrative. For the six months ended June 30, 2025, the Company
recorded stock-based compensation expense of $488,274, of which $127,123 was related to research and development and $361,151 was related
to general and administrative.

As
of